RD-138 is under clinical development by Nanjing IASO Biotherapeutics and currently in Phase I for Plasma Cell Neoplasm. According to GlobalData, Phase I drugs for Plasma Cell Neoplasm does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the RD-138 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
RD-138 is under development for the treatment of relapsed or refractory multiple myeloma or plasma cell leukemia. The therapeutic candidate comprises of autologous T cells genetically engineered through lentiviral vector to express chimeric antigen receptors (CAR) targeting G protein coupled receptor family C group 5 member D (GPRC5D).
Nanjing IASO Biotherapeutics overview
Nanjing IASO Biotherapeutics is a biopharmaceutical company that develops and manufactures tumor cell immunotherapy and antibody drugs. The company is headquartered in Nanjing, Jiangsu, China.
For a complete picture of RD-138’s drug-specific PTSR and LoA scores, buy the report here.